Insilico Medicine Revenue and Competitors

Claim your profile

Location

$306.3M

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • Insilico Medicine's estimated annual revenue is currently $41.1M per year.(i)
  • Insilico Medicine's estimated revenue per employee is $193,750
  • Insilico Medicine's total funding is $306.3M.

Employee Data

  • Insilico Medicine has 212 Employees.(i)
  • Insilico Medicine grew their employee count by 33% last year.
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$68.3M38418%$251.1M$1.7B

A company dedicated to finding novel solutions for aging and age-related diseases using advances in genomics and big data analysis. Description Our mission statement and our pledge to our investors, friends and families: Through excellence in knowledge management, machine learning and bioinformatics, relentless pursuit for new drug, omics and clinical outcomes data, development of reliable in silico drug screening methods, novel validation approaches and strong international partnerships in personalized medicine we strive to find real working solutions to cure and prevent age-related diseases and aging itself. This mission will be achieved within within the regulatory frameworks as well as the legal and ethical boundaries and by working with the outstanding scientists, academic and medical institutions and pharmaceutical companies of impeccable credibility. Our goals are: to become the first and the largest drug discovery company in aging and age-related diseases; to become the first company to fully implement the concept of personalized science, where medicine is developed, tested and validated for individual patients in a safe high-throughput environment; Some of our recent publications: Zhavoronkov A, Buzdin AA, Garazha AV, Borissov NM and Moskalev AA (2014) Signaling pathway cloud regulation for in silico screening and ranking of the potential geroprotective drugs. Front. Genet. 5:49. doi: 10.3389/fgene.2014.00049 - See more at: http://journal.frontiersin.org/Journal/10.3389/fgene.2014.00049/full#sthash.6HfgzBx9.dpuf Buzdin AA, Zhavoronkov AA, Korzinkin MB, Venkova LS, Zenin AA, Smirnov PY and Borisov NM (2014). OncoFinder, a new method for the analysis of intracellular signaling pathway activation using transcriptomic data. Front. Genet. 5:55. doi: 10.3389/fgene.2014.00055 - See more at: http://journal.frontiersin.org/Journal/10.3389/fgene.2014.00055/full#sthash.9XPxTZ3z.dpuf

keywords:Biotechnology, Pharmaceuticals, Bioinformatics

$306.3M

Total Funding

212

Number of Employees

$41.1M

Revenue (est)

33%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Insilico Medicine News

2022-04-20 - Artificial Intelligence Drug R&D Market SWOT Analysis ...

Artificial Intelligence Drug R&D Market SWOT Analysis Including Key Players – QuantumBlack, Phenomic AI, Palantir Technologies, Nq Medical, Insilico Medicine,...

2022-04-17 - Intel lends its AI to heart ultrasound analysis tech

After Eli Lilly's FDA rejection on its PD-1 drug Tyvyt, investors are pessimistic about ... Things have been escalating quickly over at Insilico Medicine.

2022-04-06 - Insilico Medicine Announces Advancement of Its Preclinical ...

Insilico Medicine is delivering breakthrough solutions to discover and develop innovative drugs for cancer, fibrosis, immunity, central nervous...

2022-04-06 - Insilico Medicine Announces Advancement of Its Preclinical ...

Insilico Medicine is delivering breakthrough solutions to discover and develop innovative drugs for cancer, fibrosis, immunity, central nervous...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$48.1M21310%N/A
#2
$48M219-13%$49.3M
#3
$65M2196%N/A
#4
$45.5M2213%N/A
#5
$52.7M228-2%N/A